Articles by Date,MENAFN

Technology

Kate Winslet Reveals Reason Why She Hadn't Directed Before

The“Titanic” star told Empire magazine: "I just decided.... I'm gonna do this.' "I had thought to myself, 'How do I answer that question?' I think I've often said, 'I've been raising a family. I've got other things going on.' But actually, I realised that the reason I hadn't directed before now was because I was probably scared." The actress, who also features in the cast of Goodbye June, said the additional scrutiny on female stars who make the move behind the camera as another factor behind her reluctance, reports co. "And I'm acutely aware of how much harder it is for actresses to turn into directors than it is for our male counterparts. I do believe there is a good deal more scrutiny placed on: 'Can they or can't they do it? What are they going to come up with?'," said the 50-year-old actress. Talking about Goodbye June, the film follows a group of siblings who come together to spend time with their terminally ill mother June played by Dame Helen Mirren in her final weeks and Kate explained that she didn't want the titular character to be "cosy". The actress said: "It was very important not to set her up as the perfect, cosy parent. When you're dealing with loss, sometimes vaguely uncomfortable, humorous things can happen. So it was important to be as real about that side of what's happening to June as possible." Winslet said directing the film was demanding, particularly as Mirren was available for just 16 days during production. She said: "I had no option but to just throw myself at it with as much energy as I could muster and just keep going. It was proper, fast-paced British filmmaking in that sense." Winslet says that the experience on Goodbye June has left her open to the prospect of directing again. She said: "I'm not saying, 'Oh, it all came naturally to me', because I don't want anything to ever come naturally to me. That's not who I am. (But) I'm relishing every single day."

Oct 13, 2025

Technology

MD. Shinha Sarder - Founder And CEO Of IT Tech BD

MD. Shinha Sarder is known as the Founder and CEO of IT Tech BD who born on 5 November , 2004. He also known as an Entrepreneur, Musical Artist, Author, Researcher, YouTuber and Content Creator. He regularly upload Content in YouTube, Facebook and other social media. He is a regular student at Computer Science and Engineering (CSE) program in the Northern University of Businesses and Technology, Khulna. He was a former student of Khulna Zilla School. His father (MD. Lutfor Rahaman) is a lawyer. His mother (Samima Sultana) is a private sector employee. He born into a Muslim family in Shirgati village, Aichgati UnionParishad, Khulna. Family and Early Life: Born into a Muslim family, Shinha grew up in a supportive and educated household. His father, MD. Lutfor Rahaman, is a respected lawyer, while his mother, Samima Sultana, works as a private sector employee. Their encouragement and guidance played a crucial role in shaping Shinha's outlook on education, discipline, and ambition.He spent his early childhood in the calm surroundings of Shirgati village, which inspired his deep connection to community and culture. Shinha's educational journey reflects his consistent dedication to learning and self-improvement. He began his schooling at the prestigious Khulna Zilla School, where he successfully completed his SSC in 2020 with a concentration in Science. Later, he pursued his HSC in 2022 from Ahsanullah College, Khulna, also from the Science Department.Currently, he is a student of Computer Science and Engineering (CSE) at The Northern University of Business and Technology, Khulna (NUBTK). His academic focus lies in software development, artificial intelligence, and digital innovation, which align closely with his professional aspirations. Career and Achievements: As the Founder and CEO of IT Tech BD, Shinha has been at the forefront of promoting technology-driven solutions and digital literacy among young learners. His vision is to build a platform where innovation meets opportunity, empowering the next generation to excel in the digital economy. In addition to his entrepreneurial ventures, Shinha is also known for his creative works as a musical artist and author. His artistic journey began with a deep love for storytelling and music, which he expressed through original compositions and written works. He has also published several creative and research-oriented writings that reflect his analytical mindset and artistic sensitivity. As a YouTuber and Content Creator, Shinha regularly uploads educational, motivational, and technical content on YouTube, Facebook, and other social media platforms. His videos often focus on personal development, technology, and creativity, inspiring thousands of viewers to follow their passions and stay motivated. Vision and Influence: Shinha's mission is to inspire youth to embrace creativity, learning, and entrepreneurship in the digital era. Through his activities on social platforms and his leadership at IT Tech BD, he continues to motivate others to use technology as a tool for positive change. Despite his young age, MD. Shinha Sarder represents a generation that believes in innovation, hard work, and continuous growth. With his commitment to education, technology, and art, he is steadily carving his place as one of Bangladesh's emerging voices in the tech and creative industries.

Oct 13, 2025

Technology

Azerion Completes Refinancing Of Outstanding Senior Secured Bonds

Press release Amsterdam, 13 October 2025 at 07:00 CEST Azerion Group N.V. completes refinancing of outstanding senior secured floating rate bonds maturing in October 2026 Azerion Group N.V. is pleased to confirm the completion of the refinancing of its outstanding senior secured bonds maturing in October 2026 with ISIN NO0013017657 (the " Existing Bonds "), with the successful early redemption of all outstanding Existing Bonds. For further information, please contact: Contact: Andrew Buckman – Chief Growth Officer About Azerion Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe's largest digital advertising and entertainment media platforms. We bring global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe, engaging, and high-quality environment, utilizing our strategic portfolio of owned and operated content with entertainment and other digital publishing partners. Having its roots in Europe and with its headquarters in Amsterdam, Azerion has commercial teams based in over 26 cities around the world to closely support our clients and partners to find and execute creative ways to make a real impact through advertising. For more information visit: This announcement is released by the Company and contains information that qualified or may have qualified as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 ("MAR"), encompassing information relating to the issuance and future listing of its new Senior Secured Callable Floating Rate Bonds due October 2029 with ISIN NO0013660357 (the "New Bonds") and redemption of the Existing Bonds described above. For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this document is released, on behalf of the Company by the contact person set out above, at the date and time set out above. This communication does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or any other financial instruments. This communication does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any New Bonds or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment whatsoever. In particular, this communication does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, or form part of any offer, invitation or solicitation to purchase, securities to any person located or resident in the United States of America, its territories and possessions (including Puerto Rico, the U.S. Virgin Island, Guam, American Samoa, Wake Island and the Northern Mariana Islands, any state of the United States and the District of Columbia (together the“United States”) or to any U.S. Person (as defined in Regulation S under the U.S. Securities Act). The securities referred to herein have not been, and will not be, registered pursuant to U.S. Securities Act or any securities laws in any state or other jurisdiction in the United Sates and may not be offered, sold, accepted, exercised, re-sold, renounced, transferred or delivered, whether directly or indirectly, in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. No public offering of securities is being, has been, or will be made in the United States. This communication is made accessible on the basis that any offers of securities referred to herein in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of such securities. The New Bonds have, with respect to persons in Member States of EEA, only been offered to persons who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation and Section 1:1 of the Dutch Financial Supervision Act. The expression "Prospectus Regulation" means Regulation No. 1129/2017. In the United Kingdom, the material is made accessible on the basis that any offers of securities referred to herein will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of such securities. The New Bonds have, with respect to persons in the United Kingdom, only been offered to persons who are qualified investors within the meaning of Article 2(1)(e) of the UK Prospectus Regulation. The expression“UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of retained EU law as defined in the EU (Withdrawal) Act 2018. The release, publication or distribution of the material may be restricted by law and persons in such jurisdictions in which a release, publication or distribution of the material should therefore inform themselves about, and observe, any such restrictions. This press release may include projections and other "forward-looking" statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of the Company about future events and financial performance. No assurances can be given that such events or performance will occur as projected and actual results may differ materially from these projections.

Oct 13, 2025

World

Shazhou Village: The Story Of Half A Quilt That Stands The Test Of Time

In autumn-winter 1934, the Central Red Army arrived in Shazhou. Three female soldiers stayed at the home of Elder Xu Jiexiu. Before leaving, they cut their only quilt in half and gave one half to her. This act stayed with Xu for life; she often told her family, "Follow the Communist Party-they'd share even their last quilt with the people." Qiao once wondered why the Red Army, short on food, clothing and equipment, still helped locals. The answer lies in the Party's core mission: the Red Army, led by the Communist Party, is a people's army dedicated to "serving the people." No matter how hard their own struggle, they shared warmth with the people-exactly what Xu meant by "the Communist Party shares its last quilt." Qiao realized the faded half-quilt is proof of the army-people bond (like fish and water) and China's national spirit of "weathering storms together." Ninety years later, Shazhou has thrived: villagers grow fruits, run guesthouses and live well through rural tourism. To Qiao, the ancestors' sentiments now shine in peacetime. Shazhou's transformation is a vivid part of China's development story. He sees China's "global community with a shared future" reflected here: true civilization lies in the warmth of sharing, even the last half of a quilt. SOURCE Hunan Today

Oct 13, 2025

Technology

Locksley Resources Qualifies For Trading On American OTCQX Market

EINPresswire/ -- Highlights >Locksley Resources Limited (ASX: LKY; OTCQX: LKYRF) has qualified to trade on the OTCQX® Best Market, upgrading from the OTCQB® Venture Market. >Trading on OTCQX enhances Locksley’s visibility and accessibility to U.S. investors, supporting its U.S.-focused critical minerals strategy. >Locksley’s flagship Mojave Project in California is strategically located adjacent to MP Materials’ Mountain Pass Mine, targeting rare earth elements (REEs) and antimony as part of a fully integrated mine-to-market strategy. >The Company’s downstream technology partnerships underpin its role in re-establishing U.S. domestic supply chains for critical materials, with a particular focus on antimony. >Rare earths and antimony are front and center in the global race to secure critical materials, with Locksley’s Mojave Project positioned at the heart of America’s efforts to restore domestic supply independence through a 100% U.S. mine-to-market strategy. OTC Markets Group Inc. (OTCQX: OTCM), which operates regulated markets for 12,000 U.S. and international securities, announced today that Locksley Resources Ltd (ASX: LKY, OTCQX: LKYRF, FSE: X5L), an exploration and development company focused on rare earths and antimony critical minerals, has qualified to trade on the OTCQX Best Market. Locksley has upgraded to OTCQX from the OTCQB Venture Market, with its symbol remaining as “LKYRF.” U.S. investors can access the company's financial disclosure and real-time Level 2 quotes on . The OTCQX Market is designed for established U.S. and international companies that are focused on investors. To qualify, companies must meet high financial standards, follow best practices for corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market is a significant milestone for companies, as it allows them to showcase their qualifications and increase visibility among U.S. investors. Investor Update Locksley’s move to the OTCQX comes amid a growing global focus on the security of rare earth minerals, which has intensified due to new export restrictions and rising trade tensions. As nations work to secure access to these critical materials, Locksley’s Mojave Project is central to America's effort to restore domestic supply independence. With a fully integrated mine-to-market strategy for both antimony and rare earths, the company is advancing a 100% American-made approach that directly supports U.S. national policy priorities and the reshoring of strategic materials. Nathan Lude, the Head of Strategy, Capital Markets & Commercialization, commented, "Graduating to the OTCQX Market in record time since our initial listing just over three months ago is a significant milestone for Locksley as we broaden our visibility and accessibility to U.S. investors. Our Mojave Rare Earths and Antimony Critical Minerals Project is strategically located in a tier-one jurisdiction adjacent to MP Materials’ Mountain Pass Mine. Locksley is positioned to play a pivotal role in reestablishing domestic supply chains through its mine-to-market strategy for critical materials, with a particular focus on antimony.” About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Its data-driven disclosure standards form the basis of its public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market, and Pink Limited™ Market. Its OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. This innovative model gives companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS™ are each SEC-regulated ATSs, operated by OTC Link LLC, a FINRA and SEC-registered broker-dealer and member of SIPC. To learn more about how they create more informed and efficient markets, visit .

Oct 13, 2025

Technology

Touareg Group Expands Global Presence With Establishment Of U.S. Technology Subsidiary

Operating from the United States, Touareg Group Technologies Co. benefits from proximity to one of the most advanced ecosystems for financial innovation and regulatory oversight. This strategic positioning allows the company to balance cutting-edge development with rigorous governance, ensuring long-term sustainability and market trust. "The creation of Touareg Group Technologies Co. is a pivotal milestone in our global expansion," said a spokesperson for Touareg Group. "Our focus is on creating sustainable shareholder value by combining technology, governance, and innovation. The upcoming cryptocurrency exchange will stand as a cornerstone of this strategy, offering a secure, compliant, and efficient marketplace that supports the growth of the digital asset industry." In addition to the exchange initiative, the subsidiary will pursue the development of advanced AI applications and institutional-grade blockchain systems. These efforts will be supported by strategic collaborations with leading technology companies, financial institutions, and regulatory authorities, ensuring alignment with global best practices and enhancing adoption across markets. The launch of Touareg Group Technologies Co. highlights the Group's broader mission to expand its international footprint, diversify its portfolio, and strengthen its position as a trusted partner at the intersection of finance and technology. By prioritizing resilience, compliance, and corporate responsibility, Touareg Group continues to build a forward-looking ecosystem that empowers businesses, communities, and shareholders worldwide. This expansion further establishes Touareg Group as a catalyst for innovation, shaping the future of finance and technology through advanced infrastructure, shareholder value creation, and sustainable growth. SOURCE Touareg Global

Oct 13, 2025

Technology

Your Body Can Be A Portable Gym: How To Ditch Membership Fees And Expensive Equipment

(MENAFN- The Conversation) You don't need a gym membership, dumbbells, or expensive equipment to get stronger. Since the beginning of time, we've had access to the one piece of equipment that is essential for strength training – our own bodies. Strength training without the use of external forces and equipment is called“bodyweight training”. From push-ups and squats to planks and chin-ups, bodyweight training has become one of the most popular ways to exercise because it can be done anywhere – and it's free. So, what is it, why does it work and how do you get started? Lawrence Crayton/Unsplash What is bodyweight training? Bodyweight training simply means you use your own body weight as resistance, instead of external weights such as barbells and dumbbells. Common exercises include push-ups, squats, lunges and sit-ups. But bodyweight training can also use static holds that challenge your body without moving, like planks or yoga poses. Bodyweight training can be used for any muscle group. Typically, we can break down the exercises by movement type and/or body region: upper body: push-ups, pull-ups, handstands lower body: squats, lunges, step-ups, glute bridges core: sit-ups, planks, mountain climbers whole body: burpees, bear crawls, jump squats. Bodyweight training can also be done with equipment: calisthenics is a style of bodyweight training that uses bars, rings and outdoor gyms. What are the main forms? Types of bodyweight training include: calisthenics: often circuit-based (one exercise after another with minimal rest), dynamic and whole-body focused. Calisthenics is safe and effective for improving functional strength, power and speed, especially for older adults yoga: more static or flowing poses with an emphasis on flexibility and balance. Yoga is typically safe and effective for managing and preventing musculoskeletal injuries and supporting mental health Tai Chi: slower, more controlled movements, often with an emphasis on balance, posture and mindful movement suspension training: using straps or rings so your body can be supported in different positions while using gravity and your own bodyweight for resistance. This type or training is suitable for older adults through to competitive athletes resistance bands: although not strictly bodyweight only, resistance bands are a portable, low-cost alternative to traditional weights. They are safe and effective for improving strength , balance, speed and physical function . What are the pros and cons? There are various pros and cons to bodyweight exercises. builds strength: a 2025 meta-analysis of 102 studies in 4,754 older adults (aged 70 on average) found bodyweight training led to substantial strength gains - which were no different from those with free weights or machines. These benefits aren't just for older adults, though. Using resistance bands with your bodyweight workout can be as effective as traditional training methods across diverse populations boosts aerobic fitness: a 2021 study showed as little as 11 minutes of bodyweight exercises three times per week was effective for improving aerobic fitness accessible and free: bodyweight training avoids common barriers to exercise such as access to equipment and facilities, which means it can be done anywhere, without a gym membership promotes functional movement: exercises like squats and push-ups mimic everyday actions like rising from a chair or getting up from the floor. difficulty progressing over time: typically, we can add weight to an exercise to increase difficulty. For bodyweight training, you need to be creative, such as slowing your tempo or progressing to unilateral (one-sided or single-limb) movements plateau risk: heavy external loads are more effective than bodyweight training for increasing maximal strength. This means if you stick to bodyweight training alone, your strength gains are more likely to plateau than if you use machines or free weights. Tips for getting started (safely) As with any form of exercise, it's always best to speak to a medical professional before starting. If you are ready to get going, here's some tips: start small: pick simple moves to begin and progress them as you gain strength, confidence and experience focus on form: think quality over quantity. Completing movements with good control and body position is more important than how many you can do with poor control progress gradually: vary the number of sets or repetitions to make your exercise more challenging. You can progress the movements from easier (push-ups on your knees) to harder (decline push-ups) as you get stronger and need more of a challenge mix it up: use a variety of types of bodyweight training as well as targeting different muscle groups and movements seek guidance: reach out to your local exercise professionals or use apps like the Nike Training Club to help guide your planning and progress. Bodyweight training means you don't need expensive equipment to improve your health. Whether it's squats in the park, push-ups at your children's football game, or yoga at home, your body is a portable gym. With consistency, creativity and time, bodyweight exercises can help you build strength and fitness.

Oct 13, 2025

Technology

S&P 500, Nasdaq Futures Rebound After $2 Trillion Rout - Trump Calms China Fears, Analysts See Pullback Fueling Next Rally

U.S. stock futures rose late Sunday, pointing to a stronger start to the week as investors looked past a painful sell-off and bet on a steadier tone in U.S.–China trade relations. Markets were set to rebound after President Donald Trump said in a social media post that trade ties with China“will all be fine,” following a volatile week of policy reversals. As of 9:30 p.m. ET on Sunday, S & P 500 futures were up 0.3%, Nasdaq 100 futures gained 1.8%, Dow futures added 0.8%, and Russell 2000 futures rose 1.6%. Trump's latest remarks eased fears of an escalation in trade tensions that had triggered a $2 trillion sell-off on Friday, according to a CNBC report. Major index-tracking ETFs ended the week sharply lower, with the SPDR S & P 500 ETF Trust (SPY) down 2.7%, the Invesco QQQ Trust (QQQ) off 3.5%, the iShares Russell 2000 ETF (IWM) falling 3%, and the SPDR Dow Jones Industrial Average ETF Trust (DIA) losing 1.9%. Analysts said the pullback appeared to be part of a routine correction rather than the start of a sustained downturn. Larry Tentarelli of Blue Chip Daily Trend Report said in a post on X that declines of 3% to 5% are typical and often precede the next leg higher, noting the importance of distinguishing between short-term resets and longer-term trend reversals. Meanwhile, Carson Group's Ryan Detrick added on X that the current bull market, even at its peak, had gained 89%, well below the 191% average rise of the previous 11 bull markets. Over the weekend, Vice President J.D. Vance urged Beijing to“choose the path of reason,” while Trump signaled an opening for Chinese President Xi Jinping, saying a full trade war would harm China more than the United States. His remarks followed Friday's announcement of a 100% tariff on Chinese goods and new export controls beginning Nov. 1, in response to Beijing's curbs on rare-earth exports. Earnings season continues Monday, with Fastenal Company (FAST) scheduled to report results before the market opens and Rocky Mountain Chocolate Factory (RMCF) set to release quarterly numbers after the close. In commodities, crude oil futures rose in early Asian trading, recovering after last Friday's sharp drop. WTI crude climbed 1.0% to $59.51 per barrel, while Brent crude gained 1.0% to $63.34. Gold futures rose 1.7% to $4,069.30 per ounce, extending recent gains. The yield on the 10-year U.S. Treasury note held steady around 4.03%, while the U.S. dollar index edged higher to 99.00, retracing part of last week's losses. Asian markets were mostly down on Monday in light trading due to a holiday in Japan. MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.6%, with South Korea's Kospi down 2.1% and Australia's S & P/ASX 200 off 0.5%. Nikkei futures traded 1.3% higher at 46,690, though still below Friday's cash close of 48,088. For updates and corrections, email newsroom[at]stocktwits[dot]com.

Oct 13, 2025

Technology

LG Energy's Q3 Operating Profit Jumps 34.1 Pc On Strong US Demand

In the three months ended September, operating profit is estimated to have surged to 601.3 billion won ($422.8 million) from 448.3 billion won in the same period last year, the company said in a regulatory filing, reports Yonhap news agency. "On top of increased ESS sales in the U.S., higher demand for small-sized cylindrical and pouch-type batteries for electric vehicles (EVs) contributed to the quarterly earnings," a company spokesperson said. Sales, however, fell 17.1 per cent to 5.69 trillion won from 6.87 trillion won amid an overall slowdown in EV sales. Looking ahead, LG Energy Solution expects sales of prismatic EV batteries to remain sluggish in the fourth quarter, as major automakers adjust their electrification strategies and maintain low inventory levels. To offset weaker EV battery demand, the company said it will focus on reducing fixed costs and securing more ESS deals in the United States, leveraging its local ESS production facility. Operating profit for the January-September period likely soared 83.3 per cent to 1.46 trillion won from 800.9 billion won a year earlier. Sales for the nine-month period are estimated to have declined 8.5 per cent to 17.53 trillion won from 19.16 trillion won a year ago. The company plans to announce its final earnings results for the September quarter later this month. Meanwhile, earlier this month, the battery maker, unveiled it plans to gradually resume officials' business trips to the United States later this month, about a month after a mass detention in Georgia. The company has suspended all trips to the U.S. after 47 of its employees and some 250 subcontractor workers were detained in a U.S. immigration raid at a construction site for a joint Hyundai Motor-LG Energy Solution battery plant on September 4, reports Yonhap news agency reported on October 2.

Oct 13, 2025

Technology

Hope, High Stakes: Egypt Hosts Pivotal Gaza Peace Summit In Sharm El-Sheikh

Co-chaired by Egyptian President Abdel Fattah Al-Sisi and U.S. President Donald Trump, the Sharm El-Sheikh Peace Summit will convene an extraordinary lineup of global leaders. Attendees include UN Secretary-General António Guterres, French President Emmanuel Macron, UK Prime Minister Keir Starmer, Turkish President Recep Tayyip Erdoğan, Jordan's King Abdullah II, German Chancellor Friedrich Merz, Spanish Prime Minister Pedro Sánchez, Italian Prime Minister Giorgia Meloni, and Greek Prime Minister Kyriakos Mitsotakis. Senior officials from the UAE, Qatar, Indonesia, Pakistan, Bahrain, Kuwait, Oman, and the Arab League are also expected, alongside European Council President António Costa. According to a statement from Egypt's presidency, the summit aims to“end the war in Gaza, strengthen efforts to establish peace and stability in the Middle East, and open a new chapter for regional security.” Proceedings will begin with a bilateral meeting between Al-Sisi and Trump, followed by a plenary session, a group photo, and speeches by the two leaders. Several heads of state are expected to hold bilateral discussions on the sidelines. A Ceasefire in Motion Diplomatic sources told Al-Araby Al-Jadeed the summit follows the announcement of a U.S.-, Egypt-, Qatar-, and Turkey-brokered ceasefire - the first phase of a broader agreement that could lead to a complete cessation of hostilities. Additional sources cited by The Wall Street Journal reported plans for a joint task force, made up of the U.S., Egypt, Qatar, and Turkey, to locate the remains of Israeli hostages still missing in Gaza. Hamas has confirmed it will not participate in the summit or attend the formal signing of the ceasefire agreement. Israeli Prime Minister Benjamin Netanyahu's attendance remains uncertain, while the Palestinian Authority has not been officially invited. However, PA President Mahmoud Abbas is said to have requested a separate meeting with President Al-Sisi during the event. Tight Security in a Tense Region Security around Sharm El-Sheikh has been significantly reinforced. Military sources report that Egypt has deployed Russian-made Buk-M2E medium-range air defense systems to safeguard the summit from potential aerial threats, including drones and cruise missiles. These systems, with a range of up to 45 kilometers, are part of a broader multi-agency security plan led by Egypt's intelligence and defense services. Gaza: Fragile Calm and Ongoing Relief In Gaza, the ceasefire has entered its third day. Hundreds of thousands of displaced Palestinians have begun returning to their homes, amid harrowing scenes of destruction. Israeli authorities have initiated the transfer of Palestinian prisoners slated for release under a new exchange deal. According to Hamas official Osama Hamdan, the exchange is set to begin Monday morning. Meanwhile, the Rafah crossing is expected to reopen for passenger movement in both directions starting Wednesday. On Sunday, 400 aid trucks carrying humanitarian supplies entered Gaza through the Rafah, Kerem Shalom, and al-Auja crossings. Field sources estimate that nearly half a million Palestinians have returned to Gaza City alone. A Turning Point? The Sharm El-Sheikh summit is widely viewed as the first major test of the fragile ceasefire framework brokered by Cairo, Washington, Doha, and Ankara. It carries the weight of global hopes - not only for an end to Gaza's longest and deadliest war since 2007 but also for the launch of a credible political process that addresses both reconstruction and long-term security guarantees. As the world watches, leaders gathering in Sharm El-Sheikh face a daunting challenge: to seize this rare moment of calm and transform it into lasting peace.

Oct 12, 2025

Technology

GPCR Structure-Based Drug Design Market Report 2025: Trends, Growth Drivers & Future Forecast Insights

G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Growth Forecast: What To Expect By 2025?In the past few years, the market size of the structure-based drug design approach for G protein-coupled receptors (GPCR) has been expanding rapidly. The market value, currently at $2.33 billion in 2024, is forecasted to escalate to $2.64 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this surge in the historic period include the increasing utilization of structure-based drug discovery techniques, heightened demand for specific therapeutic interventions, rising incidences of chronic illnesses, escalating healthcare expenditure, and the growth of approaches centered on the use of biomarkers in drug development. In the coming years, we can anticipate a significant expansion of the G protein-coupled receptors (GPCR) structure-based drug design market. Predictions show that its value will soar to $4.33 billion by 2029, reflecting a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this surge during the projected period include the proliferating demand for tailor-made medication, the widening scope of contract research organizations (CROs), escalating funds for drug discovery, the upswing in collaboration between biotech and pharmaceutical sectors, and the increasing necessity for precision drugs. Key trends during this period are expected to be technological leaps in cryo-electron microscopy and x-ray crystallography, revolutionary strides in computational docking software, advancements in AI-driven drug formulation, investment poured into high-throughput screening platforms, and innovations in peptide and antibody treatments. Download a free sample of the g protein-coupled receptors (gpcr) structure-based drug design market report: What Are Key Factors Driving The Demand In The Global G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market?The growth of the G protein-coupled receptors (GPCR) structure-based drug design market is likely to be fueled by the burgeoning demand for precision medicine. Precision medicine uses distinct biological markers to guide the creation and choice of treatments customized to the individual patient's characteristics and disease profiles. This growing demand is attributed to their higher efficacy and lesser side effects compared to conventional treatments, given that the focus in healthcare is progressively shifting towards personalized strategies that target specific molecular pathways over general wide-ranging interventions. This increased focus on precision medicine indirectly speeds up the uptake of GPCR structure-based drug design platforms because pharmaceutical firms require advanced computational tools to identify and refine receptor-specific compounds capable of delivering the molecular accuracy demanded by tailor-made treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US noted that in 2023, the FDA gave approval to 16 fresh personalized treatments aimed at rare diseases patients, a dramatic rise from the six approvals in 2022. Among these approvals, seven are cancer drugs, while three are targeted at other diseases and conditions. Consequently, the growing demand for precision medicine is a significant driver for the expansion of the G protein-coupled receptors (GPCR) structure-based drug design market. Who Are The Leading Players In The G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market?Major players in the G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Global Market Report 2025 include: • F. Hoffmann-La Roche Ltd.• Pfizer Inc.• Sanofi S.A.• AstraZeneca plc• Thermo Fisher Scientific Inc.• Boehringer Ingelheim International GmbH• WuXi AppTec Co. Ltd.• Charles River Laboratories International Inc.• Evotec SE• Acadia Pharmaceuticals Inc. What Are The Key Trends Shaping The G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Industry?Leading businesses active in the GPCR structure-based drug design market are concentrating on creating revolutionary solutions, such as structure-based drug design platforms. These platforms speed up new drug discovery and enhance therapeutic targeting by utilizing the target proteins' 3D structure to design and refine drug candidates, assisting in the identification of safer, more precise, and effective treatments. For example, in January 2025, Septerna Inc., a pharmaceutical firm headquartered in the U.S., set in motion new initiatives to progress its Native Complex Platform, following the successful procurement of $100 million series A funding. This platform facilitates structure-based drug designing for GPCRs while preserving their natural structure and movement outside the cellular environment. It backs the development of a line-up of GPCR-targeted treatments aimed at previously untreatable targets in various therapeutic fields. Moreover, it also provides a scalable basis for industrialized drug discovery, integration of innovative screening technologies, and unearthing new GPCR modulation mechanisms. The platform paves the way to a broader spectrum of therapeutic interventions by creating chances to systematically examine the entire GPCR superfamily. Analysis Of Major Segments Driving The G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market GrowthThe G protein-coupled receptors (GPCR) structure-based drug design market covered in this report is segmented as 1) By Drug Type: Small Molecule Drugs, Biologics, Peptides, Other Drug Types2) By Technology: X-Ray Crystallography, Cryo-Electron Microscopy, Computational Modeling, Nuclear Magnetic Resonance Spectroscopy, Other Technologies3) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders, Other Applications4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Other End-Users Subsegments:1) By Small Molecule Drugs: Agonists, Antagonists, Allosteric Modulators, Enzyme Inhibitors2) By Biologics: Monoclonal Antibodies, Therapeutic Proteins, Vaccines, Fusion Proteins3) By Peptides: Linear Peptides, Cyclic Peptides, Modified Peptides, Peptidomimetics4) By Other Drug Types: Nucleic Acid Based Drugs, Cell Based Therapies, Gene Therapies, Conjugated Drugs View the full g protein-coupled receptors (gpcr) structure-based drug design market report: Which Region Is Expected To Lead The G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market By 2025?In the 2025 Global Market Report for GPCR Structure-Based Drug Design, North America was projected to be the dominant region. The report covers all major global regions, including Asia-Pacific, Western Europe, Eastern Europe, South America, as well as the Middle East and Africa. Browse Through More Reports Similar to the Global G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market 2025, By The Business Research Company G Protein Coupled Receptors Global Market Report 2025report/g-protein-coupled-receptors-global-market-report Bioengineered Protein Drugs Global Market Report 2025report/bioengineered-protein-drugs-global-market-report Glp 1 Receptor Agonist Global Market Report 2025report/glp-1-receptor-agonist-global-market-report Speak With Our Expert:Saumya SahayAmericas +1 310-496-7795Asia +44 7882 955267 & +91 8897263534Europe +44 7882 955267Email: ... The Business Research Company - Follow Us On:• LinkedIn: "

Oct 12, 2025

Technology

Comprehensive Report On The Functional Genomics Market: Opportunities And Challenges

What Is The Expected Cagr For The Functional Genomics Market Through 2025?The size of the functional genomics market has seen significant expansion recently. The market size is projected to surge from $12.96 billion in 2024 to $14.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.5%. Factors contributing to the growth experienced in the historical period include an escalating emphasis on gene expression studies, greater utilization of functional assays in drug discovery, an increase in biotechnology companies, heightened development of high-throughput screening techniques, and the growing integration of bioinformatics in genomics research. The size of the functional genomics market is anticipated to experience substantial growth over the coming years, expanding to $25.19 billion in 2029, with a compound annual growth rate (CAGR) of 14.2%. This projected growth during the forecasted period can be linked to an increasing emphasis on precision medicine, a greater uptake of multi-omics methods, an escalating demand for sophisticated genetic tests, the expanding use of functional genomics in the field of oncology, and an increase in research and development investments. Key trends predicted for this period include advancements in single-cell sequencing technologies, the progress of cloud-based genomic data platforms, innovations in high-throughput functional screening procedures, advancements in the union of genomics and proteomics, and the emergence of individualized therapeutic strategies through the use of functional genomics. Download a free sample of the functional genomics market report: What Are The Driving Factors Impacting The Functional Genomics Market?The growth of the functional genomics market is projected to accelerate due to increased investment in research and development. This organized endeavor to innovate, enhance, and invent products, processes, or knowledge through intensive study and experimentation is experiencing a surge in investment. Companies are pouring more resources into this arena, driven by the pressing need to keep innovating and remain competitive in their respective fields. Not only does this achieve the development of new products and technological advancements, but it also allows firms to seize opportunities in emerging markets. Functional genomics benefit significantly from these investments as they aid in the progress of identifying and analyzing gene functions. This contributes to a deeper understanding of complicated biological processes and enables the development of precise treatments. For example, the UK government, via the Department of Health and Social Care, in December 2022, announced an investment of £105 million in an effort to expedite the diagnosis of rare genetic conditions in newborns, aiming to offer potentially life-saving treatments for many infants. This fund will facilitate research aimed at propelling genomic healthcare through the study of patients' DNA. Therefore, the functional genomics market's growth is being fueled by this surge in research and development investment. Which Players Dominate The Functional Genomics Industry Landscape?Major players in the Functional Genomics Global Market Report 2025 include:• Hoffmann-La Roche Ltd.• Thermo Fisher Scientific Inc.• Merck KGaA• Becton Dickinson and Company• Agilent Technologies Inc.• Illumina Inc.• Perkin Elmer Inc.• Revvity Inc.• Exact Sciences Corporation• Bio-Rad Laboratories Inc. What Are The Major Trends That Will Shape The Functional Genomics Market In The Future?In the functional genomics market, leading organizations are honing in on advanced methods like high-throughput sequencing to offer comprehensive and precise insights into intricate genomes. This technique allows for quick, concurrent sequencing of substantial volumes of DNA or RNA, enabling large-scale genetic information analysis. Take Roche, a pharmaceutical company based in Switzerland, as an example. In February 2025, they introduced a new category of next-generation sequencing known as sequencing by expansion (SBX) technology. This technology, which employs SBX chemistry alongside a state-of-the-art sensor module, facilitates highly efficient, high-throughput sequencing which can be customized and expanded to suit various applications. This revolutionary procedure coverts DNA or RNA sequence into an easily detectable surrogate polymer, referred to as an Xpandomer, through a specific biochemical operation. These Xpandomers, which are fifty times longer than the initial nucleic acid, transform sequence data into potent, low-interference signals that can be detected with ease and precision. This method offers standout single-molecule nanopore sequencing with both speed and versatility, thanks to the use of a CMOS-based sensor that performs parallel processing. Global Functional Genomics Market Segmentation By Type, Application, And RegionThe functional genomics market covered in this report is segmented as 1) By Product: Kits And Assays, Instruments2) By Technology: Next-Generation Sequencing (NGS), Microarray Analysis, CRISPR And Gene Editing Technologies, RNA Sequencing (RNA-Seq)3) By End-User: Academic And Research Institutes, Pharmaceutical And Biopharmaceutical Companies, Contract Research Organizations (CROs), Clinical Laboratories, Agricultural Biotechnology Companies Subsegments:1) By Kits And Assays: PCR Kits, Microarray Kits, NGS Kits, Reagents, Enzymes2) By Instruments: Sequencers, Microarray Scanners, PCR Instruments, Automation Systems View the full functional genomics market report: Which Region Holds The Largest Market Share In The Functional Genomics Market?In the 2025 Functional Genomics Global Market Report, North America holds the leading position for the specified year. Projected growth indicates that the Asia-Pacific region will experience the quickest expansion during the estimated period. The report takes into account regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Browse Through More Reports Similar to the Global Functional Genomics Market 2025, By The Business Research Company Genomics Global Market Report 2025report/genomics-global-market-report Metagenomics Global Market Report 2025report/metagenomics-global-market-report Genomics Services Global Market Report 2025report/genomics-services-global-market-report Speak With Our Expert:Saumya SahayAmericas +1 310-496-7795Asia +44 7882 955267 & +91 8897263534Europe +44 7882 955267Email: ... The Business Research Company - Follow Us On:• LinkedIn: "

Oct 12, 2025

Technology

Epidermal Growth Factor Patch Global Market Report 2025 Business Growth, Development Factors, Future Trends Till 2029

In the upcoming years, the market for epidermal growth factor patches is expected to experience rapid expansion. The market is projected to reach a value of $2.08 billion by 2029, with a compound annual growth rate (CAGR) of 13.6%. This growth during the predicted period can be credited to the rising demand for customized skincare solutions, the increase in the acceptance of advanced wound healing products, the heightened awareness of bioactive cosmetic patches, broadening uses in postoperative recovery, and a growing fondness for non-surgical skin treatments. Notable trends during the forecast period entail progress in bioactive patch formulas, the creation of combination therapy patches, innovation in sustained release delivery systems, advancements in biodegradable and environmentally-friendly materials, and the development of multifunctional skincare patches. Download a free sample of the epidermal growth factor patch market report: What Are The Factors Driving The Epidermal Growth Factor Patch Market?The growth of the epidermal growth factor patch market is set to be boosted by the rising demand for personalized medicine. Such medicine is customized to an individual's genetic background, lifestyle, and environment, thereby enhancing treatment and prevention strategies. It’s popularity is attributed to the evolutionary strides in genomics, which allows for the exact identification of genetic variations and the creation of individualized treatments. Epidermal Growth Factor (EGF) patches increase the effectiveness of personalized medicine as they locally deliver growth factors, making them perfect for wound healing and skin regeneration, thus reducing recovery time by stimulating cell growth and tissue repair, hence, improving patient-specific remedy results. For instance, in February 2024, there were reportedly 26 new personalized medicines approved by the U.S. Food and Drug Administration (FDA) according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, a major rise from 2022's 12. Therefore, the surging demand for personalized medicine is propelling the growth of the epidermal growth factor patch market. The upward trend of skin disorders is predicted to push forth the expansion of the epidermal growth factor patch market. These disorders affect the skin’s structure, function, or appearance, often resulting in inflammation, irritation, or abnormal growths. Conditions include acne, eczema, psoriasis, dermatitis, vitiligo, fungal infections, warts, and skin cancer. Environmental pollution, which destroys the skin barrier and initiates inflammatory or allergic reactions, is behind the increase in skin disorders. EGF patches aid in skin disorder treatment by strategically delivering growth factors, thus, being ideal for wounds, burns, and chronic ulcers. They stimulate cell regeneration and tissue repair, which enhances patient recovery and treatment results. For instance, Cancer Australia stated in 2023 that around 8,257 new cases of melanoma of the skin were documented, equating to 2.6% of all cancer-related deaths. Consequently, the escalating prevalence of skin disorders is propelling the epidermal growth factor patch market growth. Who Are The Major Players In The Epidermal Growth Factor Patch Market?Major players in the Epidermal Growth Factor Patch Global Market Report 2025 include:• Nissha Co. Ltd.• Daewoong Pharmaceutical Co. Ltd.• Kindeva Drug Delivery L.L.C.• LTS Lohmann Therapie-Systeme AG• Teikoku Seiyaku Co. Ltd.• Katecho Inc.• QuadMedicine Inc.• Vaxxas Pty Ltd.• DermaJect AB• Micropoint Technologies Ltd. Which Segment Accounted For The Largest Epidermal Growth Factor Patch Market Share?The epidermal growth factor patch market covered in this report is segmented as 1) By Product Type: Hydrogel Patches, Microneedle Patches, Film Patches, Other Product Types2) By Application: Wound Healing, Anti-Aging, Scar Treatment, Skin Rejuvenation, Other Applications3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels4) By End-User: Hospitals And Clinics, Dermatology Centers, Home Care, Other End-Users Subsegments:1) By Hydrogel Patches: Moisturizing Repair, Anti Aging, Scar Reduction, Wound Healing2) By Microneedle Patches: Epidermal Growth Factor Delivery, Vaccine Delivery, Pain Management, Cosmetic Treatment3) By Film Patches: Skin Brightening, Anti Wrinkle, Acne Treatment, Hydration Boost4) By Other Product Types: Cooling Soothing, Anti Inflammatory, Detoxifying, Skin Firming View the full epidermal growth factor patch market report: What Are The Regional Trends In The Epidermal Growth Factor Patch Market?In the Epidermal Growth Factor Patch Global Market Report 2025, North America dominated as the region with the most significant market share in 2024. During the forecast period, the region anticipated to exhibit the highest growth rate is Asia-Pacific. The report includes a study of different regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse Through More Reports Similar to the Global Epidermal Growth Factor Patch Market 2025, By The Business Research Company Transdermal Skin Patche Global Market Report 2025 Electronic Skin Patch Global Market Report 2025 Transdermal Drug Delivery Systems Global Market Report 2025 Speak With Our Expert:Saumya SahayAmericas +1 310-496-7795Asia +44 7882 955267 & +91 8897263534Europe +44 7882 955267Email: ... The Business Research Company - Follow Us On:• LinkedIn: "

Oct 12, 2025

Technology

Healthcare Middleware Market Projected To Reach $6.77 Billion With 12.6% CAGR By 2029

What Is The Expected Cagr For The Healthcare Middleware Market Through 2025?In recent years, there has been a significant expansion in the size of the healthcare middleware market. It is projected to increase from $3.74 billion in 2024 to $4.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.9%. The expansion during the historic period can be linked to factors such as the broader adoption of electronic health records, a growing requirement for interoperability within the healthcare systems, an escalated demand for immediate exchange of data, an increase in healthcare data volumes, and the rising utilization of connected medical appliances. In the projected time frame, the healthcare middleware market is forecasted to undergo substantial expansion, projected to soar to $6.78 billion by 2029, at a compound annual growth rate (CAGR) of 12.6%. Numerous factors are contributing to this projected growth, including the broadening of telehealth and remote patient monitoring services, an intensified focus on value-centric healthcare models, an increased uptake of cloud-based healthcare tools, a greater concentration on patient-tailored care and interaction, and the acute need for bolstered cybersecurity and data safety in healthcare structures. Major developments anticipated in this forecast period are the fusion of artificial intelligence and machine learning, the embrace of cloud-native middleware platforms, the introduction of active pharmaceutical ingredient-powered interoperability solutions, the use of blockchain for protected health data interchange, and the inclusion of IoT-facilitated middleware solutions. Download a free sample of the healthcare middleware market report: What Are The Key Factors Driving Growth In The Healthcare Middleware Market?The growth of the healthcare middleware market is anticipated to be spurred by the increasing uptake of digital health solutions. These solutions, encompassing digital technologies, tools, and platforms, aim to enhance health outcomes, the delivery of healthcare, and patient engagement. The surge in digital health integration is fueled by the rising demand for accessible remote healthcare, as healthcare providers and patients alike seek accessible, time-efficient substitute for face-to-face consultations. Through linking electronic health records (EHRs), medical devices, and telehealth platforms, healthcare middleware facilitates digital health. It allows for the seamless real-time exchange of data while securing interoperability, scalability, and the safe flow of information, thus improving the delivery of remote care. For example, in June 2022, the Department of Health and Social Care, a UK government body, announced that it's expected that by March 2025, all NHS trusts will have embraced electronic health records, a noticeable increase from the 90% that had adopted them by December 2023. As such, it is clear that the accelerating adoption of digital health solutions is propelling further the expansion of the healthcare middleware market. What Are The Top Players Operating In The Healthcare Middleware Market?Major players in the Healthcare Middleware Global Market Report 2025 include: • Redox Inc.• InterSystems Corporation• Edifecs Inc.• Innovaccer Inc.• Orion Health Group Ltd.• Verato Inc.• 1upHealth Inc.• Health Gorilla Inc.• Validic Inc.• CareEvolution Inc. What Are The Top Trends In The Healthcare Middleware Industry?Key healthcare middleware market operators are concentrating on creating advanced solutions like transformative healthcare solutions for enhancing clinical decision-making, improving interoperability and facilitating efficient patient care delivery. These cutting-edge healthcare technologies and approaches employ data, advanced analytics, and digital tools to revolutionize the management, experience, and delivery of healthcare. They aim to lower costs, enhance patient outcomes, and streamline workflows. For example, in January 2025, Vim Inc., an American connected healthcare technology company, introduced Care Insights. This transformative healthcare solution is designed to include patient-specific suggestions. It integrates actionable patient-specific data directly into native EHR workflows to improve the management of diagnosis and care gaps. It also strengthens provider decision-making by integrating data from various sources, delivering real-time suggestions, which leads to better decisions within the ongoing clinical workflows, ultimately improving patient care outcomes. Comprehensive Segment-Wise Insights Into The Healthcare Middleware MarketThe healthcare middleware market covered in this report is segmented as 1) By Type: Communication Middleware, Platform Middleware, Integration Middleware, Other Types2) By Deployment: On-Premises Models, Cloud-Based Models, Hybrid Models3) By Application: Clinical, Financial, Operational, Administrative4) By End-User: Healthcare Payers, Healthcare Providers, Life Science Organization, Clinical Laboratories, Other End-Users Subsegments:1) By Communication Middleware: Message-Oriented Middleware, Remote Procedure Call Middleware, Data Distribution Service Middleware, Event-Driven Middleware2) By Platform Middleware: Database Middleware, Application Server Middleware, Web-Based Middleware, Transaction Processing Monitor Middleware3) By Integration Middleware: Enterprise Service Bus Middleware, Application Programming Interface Management Middleware, Business Process Management Middleware, Cloud Integration Middleware4) By Other Types: Mobile Middleware, Embedded Middleware, Internet Of Things Middleware, Legacy System Integration Middleware View the full healthcare middleware market report: Global Healthcare Middleware Market - Regional InsightsIn the 2025 Global Market Report for Healthcare Middleware, North America stood as the leading region in the previous year, 2024. It's projected that the most rapid expansion will come from the Asia-Pacific region. The report encapsulates data from regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. Browse Through More Reports Similar to the Global Healthcare Middleware Market 2025, By The Business Research Company Home Healthcare Software Global Market Report 2025 Healthcare Software As A Service Global Market Report 2025 Healthcare Technology Global Market Report 2025 Speak With Our Expert:Saumya SahayAmericas +1 310-496-7795Asia +44 7882 955267 & +91 8897263534Europe +44 7882 955267Email: ...The Business Research Company - Follow Us On:LinkedIn

Oct 12, 2025

Technology

Daniel Pompa Leads Breakthrough Health Program To Restore Cellular Function And Boost Energy

Los Angeles, CA , Oct. 12, 2025 (GLOBE NEWSWIRE) -- In 2025, individuals struggling with fatigue, brain fog, and chronic health challenges are finding renewed hope through the Pompa Program. Under the leadership of Daniel Pompa, this transformative initiative harnesses the power of cellular detox and metabolic healing to restore balance, energy, and vitality in daily life. Pompa Program Powered by science and inspired by transformation, the Pompa Program is revolutionizing the way people approach detox and recovery. Under Daniel Pompa's leadership, participants move through Core Prep, Body, and Brain kits that awaken cellular health and restore metabolic balance. The Core Prep Kit supports drainage through the liver, kidneys, and gut while preparing the body for detox. The Core Body Kit advances systemic cleansing, flushing stored toxins from tissues and organs. The Core Brain Kit provides targeted neuro-detoxification, helping to remove toxins from the brain and nervous system. Each phase represents a journey of renewal. As toxins are cleared and neuro-repair pathways activate, the body begins to rediscover what proper balance feels like. Weeks build into months of steady transformation, sharper thinking, increased energy, and more consistent focus. Over the course of 12 months, participants engage in mentorship and one-on-one coaching that feels more like a collaborative partnership than a traditional instructional approach. Lifetime access ensures the journey continues and evolves alongside each individual's progress. Ultimately, the detox process becomes more than a protocol; it transforms into a full return of vitality at the cellular level. The Pompa Program framework integrates nutraceuticals, personalized nutrition, metabolic support, and one-on-one coaching to correct dysfunction at its cellular source. Participants work with trained coaches to identify upstream factors, such as heavy metal exposure, hormonal imbalances, and gut dysbiosis, that drive inflammation and cellular damage. By targeting these sources, the program restores cell function and prepares the body for lasting recovery. This cellular-centered approach has produced hundreds of success stories among participants. One graduate reported losing 21 pounds in four weeks, while another regained the freedom to enjoy outdoor activities pain-free and energetic again. Many participants experience renewed vitality and hormonal balance after years of struggling with conventional methods, demonstrating how guidance and education create lasting detox results. This commitment to structured support reflects Daniel Pompa 's philosophy. Each participant begins with a free webinar that introduces the science of cellular healing. They then collaborate with a Pompa-trained health coach to develop a personalized plan for detox and metabolic renewal. Throughout the 12-month program, participants maintain lifetime access to an online portal and attend weekly live Q&A sessions with Dr. Pompa. These interactive sessions sustain engagement and empower participants long after they complete the program. In an age where fatigue and toxicity affect millions, the Pompa Program offers a proven path to restoration. Guided by Daniel Pompa , participants gain practical tools and support to detoxify their bodies, restore metabolic balance, and improve overall wellness. This approach transforms daily routines into meaningful steps toward long-term vitality and sustainable health. To discover how the Pompa Program restores vitality through cellular detox, visit . About Pompa Program The Pompa Program is more than a wellness system; it's a movement reshaping how people think about healing. Founded by Daniel Pompa, it rejects symptom-chasing and instead teaches the art of restoring health from the cell outward. Every protocol is built on one conviction: when the cell wakes up, the body follows. From uncovering hidden toxins to reawakening metabolism and vitality, the program guides individuals on a scientific yet deeply personal journey back to their full human potential. In the world of quick fixes and surface-level solutions, the Pompa Program stands for something rare: truth, transformation, and the freedom of genuine health. Media Contact The Pompa Program Address: 3250 Glendale Blvd, Los Angeles, CA 90039, Suite 477Phone: +1 (800) 691-7422Website

Oct 12, 2025

Technology

DRG Elevates Executive Decision-Making: What Pharma Teaches Us About Innovation Vetting

EINPresswire/ -- In arenas like biotech, digital health, medtech, and beyond, promoters extoll “breakthroughs” on a near-daily basis. The challenge for executives is not lack of opportunity, but distinguishing real, scalable innovation from hype. Desk Research Group (DRG) is turning to one of the world’s most rigorous sectors, pharmaceutical R&D, to craft a cross-industry decision framework that brings discipline to executive investments and strategic pivots. DRG’s latest insight piece, “What Pharma Teaches Us About Discovery: 5 Filters for Executive Decision Making,” adapts pharma’s high-stakes, evidence-first approach into pragmatic filters usable in health, technology, manufacturing, and adjacent sectors. The insight has struck a chord, and now DRG is backing it with advisory offerings to help clients integrate filter-based decision governance into their highest-stakes bets. “Pharma doesn’t survive on marketing claims. It survives on replicable trials, regulatory scrutiny, and reproducible impact,” says Chris (Founder, DRG). “We saw parallels in other industries: many “disruptive” propositions sound dazzling, until you test them against rigorous, cross-sector filters. That’s the gap DRG is helping executives close.” Five Pharma-Inspired Filters: From Lab to Boardroom - In DRG’s framework, each innovation or strategic option must pass all five filters, not just perform well in one area. These filters are: 1) Evidence Quality > Is there methodologically sound, auditable validation (akin to randomised trials)? 2) Meaningful Outcomes > Do gains translate into real business or patient value (not vanity metrics)? 3) Effect Size Reality > How big is the impact, and is it reliably measurable? 4) Replicability & Scalability > Can performance be duplicated in heterogeneous settings? 5) Risk & Safety Margins > What are downside bounds, failure modes, or negative externalities? These filters move beyond “Can it work in a lab?” to “Will it work in the real world, repeatedly, at scale?”, a shift many sectors struggle with. DRG’s insight lays out how to apply each filter pragmatically: scrutinise sample sizes, test baselines, compare claimants to unbiased controls, and stress-test worst-case scenarios. Why This Matters Today (Especially in Healthcare & Pharma) Within the Healthcare & Pharmaceutical sectors, DRG already provides deep domain research, competitive intelligence, regulatory landscaping, and strategic analysis. But the same rigor that underpins pharma’s discovery cycles is often absent in digital health, medtech, or crossover biotech investments. Overpromising, underdelivering, and regulatory misfires are common pitfalls, even for well-funded ventures. By combining DRG’s sector expertise with this decision-filter lens, clients gain a systematic way to: - Vet innovation partners > Determine which startups or technologies are truly robust - De-risk internal R&D pipelines > Apply filters early to avoid expensive sunk costs - Translate regulatory and clinical rigour across domains > For example, adapting pharma-level standards to adjacent life sciences - Bridge silos between tech and biology > Ensuring AI, diagnostics, or digital therapeutics aren’t just flashy, but viable Moreover, the cross-industry framing allows non-pharma executives (in health-adjacent sectors) to import rigor from a high-bar field, elevating standards across the board. DRG’s Advisory Offer: Embed Filters Into Strategy DRG is not just publishing theory, it is activating it. The firm now offers a Decision Filter Integration service within its Healthcare & Pharmaceutical practice: - Diagnostic workshop: Assess your current decision governance, investment processes, and approval workflows - Filter customisation: Tailor the five filters to your organisation’s risk tolerance, domain nuance, and investment scale - Pilot application: Test the filters on two to three active “innovations under consideration” - Governance embedding: We integrate filter checkpoints into strategic review cycles, due diligence, and post-mortem review templates - Ongoing guardrails: As innovations evolve, filters evolve > DRG maintains calibration and periodic reassessment The offering aligns tightly with DRG’s core promise: clarity in complexity. It gives boards, innovation teams, and R&D leaders a way to institutionalise guardrails against hype, without stifling agility. Client Use Case (Anonymised, Composite Insight) A mid-sized healthtech firm considering investment in a diagnostics startup recently engaged DRG. When run through DRG’s filters: - The evidence quality was weak > claims based on a small pilot with statistical irregularities - The effect size was overstated > the projected benefit, when normalised, was incremental - Replicability failed when tested across multiple geographies - Risk margins were unquantified > downside clinical risk and False Positives were ignored Because the startup failed several filters, DRG recommended alternative strategies: redesigning the diagnostic’s validation pathway, running a more robust clinical study, or negotiating contingent contracts. The client avoided a potentially multimillion-dollar misstep and instead scaled a stronger path forward. Media & Executive Outreach The timing is fertile: - Venture capital and corporate innovation arms are aggressively funding life science and health-tech bets - Regulatory regimes (FDA, EMA, etc.) are tightening standards on diagnostics, AI in medicine, and real-world validation - Cross-sector convergence (AI + biotech, telemedicine + devices) demands rigorous lenses to avoid “shiny toy syndrome” DRG plans to amplify this insight through webinars, white-papers, and executive roundtables, especially targeting C-suite leaders, innovation teams, venture groups, and health funders. About DRG & Healthcare Practice: Desk Research Group, with 25+ years of experience, specialises in market and industry research, strategic planning, competitive intelligence, and horizon foresight. Each engagement is senior-led and built around translating research into decision-ready strategy. Within Healthcare & Pharmaceutical, DRG offers domain-specific capabilities: regulatory mapping, clinical market landscaping, competitive benchmarking, reimbursement pathways, and innovation portfolio strategy. Through combining deep domain insight with the discipline of pharma’s decision filters, DRG is helping organisations across life sciences, medtech, digital health, and adjacent sectors make smarter, safer, more scalable innovation choices. To learn more, read the full insight: Visit DRG’s healthcare practice: Or contact ... to schedule a briefing or pilot engagement.

Oct 12, 2025

Technology

Genomic And Proteomic Tool Market Forecasted To Achieve US $51.19 Billion By 2029

How Big Is The Genomic And Proteomic Tool Market In 2025?The market size of genomic and proteomic tools has witnessed swift expansion in the past few years. The market, which was valued at $29.63 billion in 2024, is predicted to grow to $33.14 billion in 2025 with a compound annual growth rate (CAGR) of 11.8%. This growth in the historical duration can be traced back to the increasing cases of cancer and rare diseases, the expansion of academic core laboratories, a rise in healthcare expenditures by affluent nations, the establishment of standardized clinical guidelines for molecular testing, and widespread reimbursement for molecular diagnostics. In the upcoming years, the genomic and proteomic tool industry is projected to experience a significant expansion, reaching a market valuation of $51.20 billion by 2029, with a compound annual growth rate (CAGR) of 11.5%. Factors contributing to this development during the forecast period include the rising aging population with an increasing chronic disease burden, incorporation of precision medicine within national healthcare systems, extended biomarker testing coverage by payers, molecular stratification driven clinical trial growth, and the embrace of value-based care, favoring targeted therapies. The forecast period will also see key trends such as advancements in deoxyribonucleic acid long-read sequencing, enhanced throughput in single-cell ribonucleic acid sequencing, simultaneous detection of ribonucleic acid and proteins in situ, use of digital polymerase chain reaction for precise quantification, and the application of trapped ion mobility spectrometry for proteomic analysis. Download a free sample of the genomic and proteomic tool market report: What Are The Key Driving Factors For The Growth Of The Genomic And Proteomic Tool Market?The rise in the usage of personalized medicine is set to fuel the expansion of the genomic and proteomic tool market in the future. Customized medical care involves preventing, diagnosing, and treating a person based on their molecular makeup determined through the use of biomarkers from DNA, RNA, and proteins. This surge in the acceptance of personalized medicine is driven by progress in genomics, proteomics, and biomarker discovery which makes custom treatments possible according to a person's genetic makeup, promoting demand for targeted therapies, superior diagnostic methods, and high-precision health care solutions. Advances in the fields of genomics, proteomics, and biomarker discovery have made the creation of customized therapies and accurate diagnostics based on a patient's genetic makeup a feasible reality. Genomic and proteomic instruments are imperative in identifying genetic variations and protein biomarkers, thereby allowing medical professionals to fine-tune treatments and enhance patient health outcomes. For example, in February 2024, the US-based nonprofit, Personalized Medicine Coalition, along with the United States Food and Drug Administration (FDA), gave approval to 16 new personalized treatments for patients suffering from rare diseases, a significant rise from just 6 approvals in 2022. Hence, the rising acceptance of personalized medicine is fueling the expansion of the genomic and proteomic tool market. Who Are The Key Players In The Genomic And Proteomic Tool Industry?Major players in the Genomic And Proteomic Tool Global Market Report 2025 include:• F. HoffmannLa Roche• Thermo Fisher Scientific Inc.• Danaher Corporation• Merck KGaA• Becton, Dickinson and Company• GE Healthcare• Eurofins Scientific SE• Agilent Technologies Inc.• Illumina Inc.• Bruker Corporation What Are The Key Trends Shaping The Genomic And Proteomic Tool Industry?Significant firms in the genomic and proteomic tools industry are emphasizing innovation by making use of spatial multi-omics technologies. These technologies enable the detection of RNA and proteins in the same cell and in-situ, facilitating the integration of molecular data layers, the conservation of tissue architecture, and the speeding up of discoveries. Spatial multi-omics technology allows for concurrent measurements of gene expression and protein markers in intact tissue at either single-cell or subcellular resolution, providing deeper biological insights compared to single-modality assays. For instance, in August 2025, 10x Genomics, a biotechnology company based in the U.S., launched Xenium Protein. This is a pioneer assay for single-cell RNA and protein analysis on the Xenium in situ platform. This unique offering provides a seamless workflow on a single instrument, saving time by negating the need for cross-platform data integration, and includes validated protein sub-panels that are ready-to-use, simplifying setup and quality control. These developments allow scientists to retain spatial context while expanding biomarker panels, benefitting applications such as target validation, patient stratification, and studies of the mechanism of action. What Segments Are Covered In The Genomic And Proteomic Tool Market Report?The genomic and proteomic tool market covered in this report is segmented as1) By Product Type: Instruments, Consumables, Software, ServicesBy Technology: Sequencing, Microarray, Polymerase Chain Reaction (PCR), Mass Spectrometry, Electrophoresis, Chromatography3) By Workflow Stage: Sample Preparation, Library Preparation, Data Analysis, Reporting4) By Application: Drug Discovery, Diagnostics, Personalized Medicine, Agriculture And Animal Research5) By End User: Academic And Research Institutions, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Healthcare Providers Subsegments:1) By Instruments: DNA Sequencing Systems, Polymerase Chain Reaction (PCR) Systems, Microarray Analyzers, Mass Spectrometry Instruments, Electrophoresis Systems, Chromatography Instruments, Flow Cytometers2) By Consumables: Reagents And Kits, Assay Kits, Sample Preparation Consumables, Sequencing Consumables, Protein Assay Reagents, Microarray Chips, Laboratory Chemicals3) By Software: Genomic Data Analysis Software, Proteomic Data Analysis Software, Bioinformatics Platforms, Clinical Data Interpretation Tools, Workflow Management Software, Cloud-based Analysis Platforms4) By Services: Next-Generation Sequencing (NGS) Services, Gene Expression And Genotyping Services, Protein Identification And Quantification Services, Biomarker Discovery Services, Structural Biology Analysis Services, Bioinformatics And Data Interpretation Services, Molecular Diagnostics Services View the full genomic and proteomic tool market report: Which Region Is Expected To Lead The Genomic And Proteomic Tool Market By 2025?In 2024, North America dominated the global genomic and proteomic tool market, while Asia-Pacific is predicted to experience the most rapid growth over the forecast period. The report includes data from seven regions: North America, Asia-Pacific, Western Europe, Eastern Europe, South America, and the Middle East and Africa. Browse Through More Reports Similar to the Global Genomic And Proteomic Tool Market 2025, By The Business Research Company Proteomics Global Market Report 2025/report/proteomics-global-market-report Genomics Global Market Report 2025/report/genomics-global-market-report Genomics Services Global Market Report 2025/report/genomics-services-global-market-report Speak With Our Expert:Saumya SahayAmericas +1 310-496-7795Asia +44 7882 955267 & +91 8897263534Europe +44 7882 955267Email: ...The Business Research Company - Follow Us On:• LinkedIn: "

Oct 12, 2025

Technology

Freeher Vermont And The National Council Celebrate Major Victory: No New Women's Prison In Essex

"When people come together to demand transparency, accountability, and justice, we win. And this week, Vermont won." "This victory belongs to the people," said Andrea James , Founder and Executive Director of The National Council. "It belongs to the organizers, the neighbors, the women, and the families who refused to let a new prison rise in their community. When people come together to demand transparency, accountability, and justice, we win. And this week, Vermont won." For years, FreeHer Vermont has been on the ground - canvassing, attending hearings, and keeping residents informed while the Department of Corrections attempted to push forward plans behind closed doors. Their work ensured that local voices, not bureaucratic interests, would shape their town's future. "This decision gives Vermont a chance to choose a different path," said Jayna Ahsaf , Director of FreeHer Vermont. "Instead of wasting $90 million on cages, Vermont can invest in what truly keeps people safe - housing, flood recovery, mental health care, and education. The future of Vermont depends on care, not confinement." The National Council and FreeHer Vermont are calling on state leaders to pass a moratorium on all new prison construction and redirect resources toward initiatives that strengthen communities and expand opportunity. "Vermont can lead the nation by example," James added. "We don't need new prisons. We need new priorities - rooted in care, compassion, and community." About The National Council The National Council for Incarcerated and Formerly Incarcerated Women and Girls is a national organization working to end the incarceration of women and girls and to build alternatives led by directly affected people. Through advocacy, organizing, and research, The National Council uplifts the voices of women impacted by incarceration to drive systems change. About FreeHer Vermont FreeHer Vermont is a grassroots chapter of The National Council, organizing across Vermont to stop prison expansion and build community-based solutions to harm, addiction, and poverty. For media inquiries: [email protected] SOURCE The National Council for Incarcerated and Formerly Incarcerated Women and Girls

Oct 12, 2025

Technology

Nouscom Presents Positive Phase 2 Results Of NOUS-209 Immunotherapy Combined With Pembrolizumab In MSI-H Metastatic Colorectal Cancer Patients Refractory To Anti-PD-1 Therapy, At ESMO 2025

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients either don't respond or develop resistance leading to disease progression, leaving limited treatment options. Results from this Phase 2 study of NOUS-209 in combination with pembrolizumab in MSI-H mCRC patients refractory to anti-PD-1 therapy demonstrate clinical activity including objective responses and strong disease control in this difficult-to-treat patient population. NOUS-209 further induced robust immune activation in the majority of patients. Retreatment at 6 months induced a strong, durable and polytopic T cell immune response correlating with clinical response. NOUS-209 monotherapy is also being developed for cancer interception in Lynch Syndrome (LS) carriers, with a registration-enabling Phase 2/3 study in preparation following positive Type B and C FDA meetings. BASEL, Switzerland – 13 October 2025 – Nouscom, a clinical-stage biotech company developing next-generation neoantigen-targeted off-the-shelf and personalized cancer immunotherapies, today announced positive results from a completed Phase 2 trial evaluating NOUS-209 in combination with pembrolizumab for patients with microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) who are refractory to anti-PD-1 therapy. Results from this Phase 2 trial will be presented in a poster session at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting, taking place in Berlin, Germany, from 17 to 21 October 2025. Study Highlights: NOUS-209 is an off-the-shelf viral vector-based immunotherapy targeting frameshift peptides specifically expressed on deficient mismatch repair (dMMR)/MSI-H tumors, thereby harnessing the power of the immune system to recognize and eliminate MSI-H cancer cells. Anti-PD-1 therapy is the approved first-line standard of care in dMMR/MSI-H mCRC, but resistance or relapse can develop, requiring the development of new treatment options. In this Phase 2 trial, NOUS-209 combined with pembrolizumab was administered to 20 evaluable patients with dMMR/MSI-H mCRC who had progressed on prior anti-PD-1 treatment (77% had received prior single agent anti-PD-1 therapy, 23% received combination therapy with anti-CTLA-4). The median number of prior lines was 2 (1-7). The primary endpoint was Objective Response Rate (ORR); secondary endpoints included progression-free survival (PFS) and safety, with immunogenicity as an exploratory endpoint. Key Results: ORR was 15% (3 partial responses), with a disease control rate (DCR) of 70% (11 stable disease, 6 progressive disease). Median progression-free survival (PFS) was 6.4 months. Safety profile remained favorable, with no emerging findings. Robust immune activation was detected in 80% of patients. Seven patients (32%) were retreated with NOUS-209 at 6 months; among those, 86% remained in stable disease and 14% had a partial response, with the latter demonstrating induction of a strong, durable and polytopic T cell immune response with a desired effector memory phenotype and correlating with clinical response. “There remains a high unmet need for effective therapies that can overcome anti-PD-1 resistance and provide durable disease control. These data are promising in this difficult-to-treat patient population given the modest clinical benefit of approved options in the same setting,” said Javier Ros, MD PhD, from Vall d'Hebron University Hospital . “These clinical data are very encouraging. NOUS-209 combined with pembrolizumab has demonstrated meaningful disease control and immune activation in patients who have exhausted anti-PD-1 therapy,” said Dr. Sven Gogov, Chief Medical Officer of Nouscom . “We are excited by the overall positive clinical dataset emerging from the completed clinical trials of NOUS-209, not only in MSI-H mCRC patients but also the Phase 1b/2 results in Lynch Syndrome carriers that were presented earlier this year at AACR. These results support our commitment to advancing NOUS-209 into a registration-enabling study for cancer interception in Lynch Syndrome carriers,” said Dr. Marina Udier, Chief Executive Officer of Nouscom . Details of the abstract and presentation at ESMO : Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results Poster Number: 802P Session: Colorectal Cancer Poster Session Session Time/ Place: Sunday October 19 / 12:00-12:45 (CEST) / Hall 25 The abstract is available on the ESMO website, here . About MSI-H mCRC Refractory to anti-PD-1 Therapy Microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) is a biologically distinct subtype of colorectal cancer characterized by mismatch repair deficiency. While anti-PD-1 +/- anti-CTLA4 therapies are approved in the first line treatment setting in this population, over 50% of patients do not respond to initial therapy and many responding patients eventually develop resistance and progress, leaving limited treatment options. There remains a high unmet need for effective therapies that can overcome resistance and provide durable disease control in these patients. About Lynch Syndrome Lynch Syndrome (LS) is a common inherited condition that significantly increases a person's risk of developing cancer over their lifetime, especially colorectal cancer (CRC) (up to 50% risk, compared to 2% for general population), endometrial cancer (up to 50% risk, compared to 1-2% for general population) and urothelial cancer (up to 25% risk, compared to 1-2% for general population)1,2,3,4. LS also elevates the risk of developing other cancers including gastric, ovarian, prostate and pancreatic. LS is caused by inherited mutations in specific genes responsible for repairing DNA, leading to the buildup of harmful genetic errors that can accumulate, triggering development of tumors. Currently, managing LS is limited to frequent screenings - such as colonoscopy to try to catch cancer early, but which will not prevent cancer incidence5 - or elective surgery, which is invasive, expensive and negatively impacts quality of life. As a pioneering approach to cancer interception, Nouscom's investigational immunotherapy, NOUS-209, is designed to train the immune system to recognize and stop cancer before it develops. About Cancer Interception Cancer interception is an innovative approach that aims to stop cancer in its earliest stages, before tumors fully develop and spread. Unlike traditional therapies that target established cancers, interception strategies harness advancements in immuno-oncology that are able to train the immune system to recognize and eliminate precancerous and cancerous cells. This approach is particularly crucial for those with high-risk genetic conditions such as LS who are predisposed to developing microsatellite instability (MSI) -associated cancers. About NOUS-209 NOUS-209 is an investigational off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H). These tumors produce unique markers known as frameshift peptide (FSP) neoantigens, which are unique to cancerous cells and absent in healthy cells. NOUS-209 is comprised of two proprietary viral vectors able to deliver 209 shared FSP neoantigens and train the immune system to recognize and attack cancerous and pre-cancerous cells before tumors can develop. Phase 1b/2 data (NCT0507886656) demonstrated the safety of NOUS-209 and its ability to stimulate potent immune responses in LS carriers7, supporting its advancement into a potentially registration-enabling Phase 2/3 trial in cancer interception. It is also being studied in a randomized Phase 2 study in combination with pembrolizumab for the first line treatment of advanced dMMR and/or MSI-H mCRC. Data published from the successfully completed Phase 1b trial were published in Science Translational Medicine8. About Nouscom Nouscom is a clinical-stage biotech company pioneering next-generation neoantigen-targeted immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease. Its proprietary viral vector platform enables broad and durable immune activation by delivering optimized neoantigens that train the immune system to recognize and fight cancer. Nouscom's lead program, NOUS-209, is an off-the-shelf immunotherapy in advanced clinical development for cancer interception in LS and the treatment of MSI-mCRC. The company's clinical stage portfolio also includes NOUS-PEV, a personalized neoantigen immunotherapy, with published data from a successfully completed Phase 1b trial9. For more information on Nouscom, please visit the company's website at or follow us on LinkedIn . References Contacts NouscomRick Davis, COO... +41 61 201 1835 MEDiSTRAVASylvie Berrebi, Sandi Greenwood, Mark Swallow... +44 (0)203 928 6900

Oct 12, 2025

Technology

Monster Energy's Marine Cabirou Claims First Place At 2025 UCI Downhill Mountain Bike World Cup In Mont-Sainte-Anne

Also rising to the podium, 28-year-old Luca Shaw from Hendersonville, North Carolina, claimed second place in Elite Men with an intense run. Shaw finishes his 2025 season in third place on the overall UCI Downhill Mountain Bike World Cup rankings. From October 9-12, the 2025 UCI Downhill Mountain Bike World Cup contested the final race of the season at legendary Mont-Sainte-Anne, Canada. After a tumultuous season with eight races across Europe as well as one round at Lake Placid, New York, riders were eager for the final showdown. Located in the Laurentians mountains near Quebec City, the legendary Mont-Sainte-Anne track has been hosting the UCI World Cup since 1998, making it the longest-running venue on the circuit. This edition marked the 30th UCI World Cup for the bike park, and the festive energy was palpable among riders and over 35,000 spectators live on-site for the big race. In the Elite Women's final, the high-energy crowd celebrated Monster Energy's Cabirou on her road to victory. After qualifying in fifth place, the French team rider turned up the heat when it counted and finished in first place, mere fractions of a second ahead of her competitors. Cabirou found herself managing difficulties on the first split, squeezing into the next section in seventh place. But once she found her line, Cabirou posted the second-fastest times of the day on Split 2 and Split 3 before taking top position in the final stages of the race. With a final time of 3:34.905, Cabirou claimed the victory at Mont-Sainte-Anne as the second UCI World Cup win of the season. "It's incredible to take the win today at this venue," said Cabirou. "To end the season like this is a dream come true. I had some tough results this year, mixed with some really good ones, so this one felt really nice. I made a few big mistakes during my qualification run and had to switch up some lines this morning, which paid off! I gave it my all, and to win my 11th World Cup here is amazing!" The victory concludes a difficult season for Cabirou on a high note. In July, she suffered a heavy crash that required hospital treatment at the World Cup in Pal Arinsal, Andorra, and missed the following race. She recovered quickly and also previously took first place at the World Cup in Val di Sole, Italy to boost her score. Overall, Cabirou finished her 2025 season in fifth place with 1280 points. Concluding her race at Mont-Sainte-Anne in 13th place, 35-year-old Camille Balanche from Le Locle, Switzerland, concluded her 2025 season in sixth place overall with 1176 points. It's a bittersweet moment for the iconic rider, as Mont-Sainte-Anne marks the final race before Balanche's retirement from professional mountain bike racing. In a storied career, Balanche claimed the 2019 European Championship title, took first place in the 2020 Downhill World Championship at Leogang, and earned the 2022 UCI Downhill World Cup overall title. She earned 13 podium finishes in World Cup events, including four victories, and pushed the progression in women's mountain bike racing. Thank you from everyone at Monster Energy! The Elite Men's division final stoked fans with fast leaderboard shifts and performances worthy of a season finale. In the intense battle on the steep and technically challenging course that sidelined several favorites, Monster Energy's Shaw dropped in as one of the top competitors. Just one weekend prior, the North Carolina local took second place at the season's only stop in the United States at Lake Placid. Could he close out the season on the podium in Canada? He sure could! After qualifying for Saturday's final in second place, Shaw once again proved his ability to perform under immense pressure. Working the course with unique lines, the American rode outside of podium contention for the majority of the race. But after finishing Split 4 as the day's fourth-fastest rider, Shaw edged out second place on the final stretch with a finish time of 3:32.340. "That was so hard. The track actually dried up a lot and became so slippery in some sections that it became tough to gauge between sectors," said Shaw. "I felt so good again this weekend, and I was pretty happy to put down a clean fast run! I crossed the line pleased with what I've done, and that also translated to a second place to finish off the season. I'm over the moon with that. It's a super long and demanding track, and to have a perfect run is really hard here, so I'm stoked on my day for sure. Thanks for all the support this season! See you in '26!" Saturday's podium finish puts Shaw into third place in the overall 2025 UCI Downhill Mountain Bike World Cup rankings with 1366 points. Also making the top five in the 2025 season results, 28-year-old Loris Vergier from Cagnes-sur-Mer, France, took fourth place overall. Vergier earned his score of 1199 points with standouts including his second place at the World Cup in La Thuile, Italy. Trailing close behind, 29-year-old Amaury Pierron from Brioude, France, took fifth place in overall standings on the strength of 1170 points. Also looking back on a difficult season, Pierron fractured his collarbone in a crash on the first day of practice in Val di Sole, Italy, in June. Undeterred, he quickly rebounded and claimed the victory at the Lenzerheide World Cup in September. Finishing his 2025 UCI Downhill Mountain Bike World Cup season in sixth place, 31-year-old Troy Brosnan from Adelaide, South Australia, scored 1018 points. The Australian's season highlight was his second-place finish at the Val di Sole round in June. Also noteworthy, 21-year-old Ryan Pinkerton capped his 2025 season with a breakthrough performance, taking fifth place at Mont-Sainte-Anne and eighth at Lake Placid. Recently promoted from the Monster Army program to the Monster Energy pro team ahead of Lake Placid, the American rider demonstrated major progress and consistency, finishing the year strong, ending 11th overall in the 2025 standings. Congrats to all Monster Energy athletes and Monster Army riders on a strong 2025 UCI Mountain Bike Downhill World Cup season! For more on Marine Cabirou , Luca Shaw , Camille Balanche , Loris Vergier , Amaury Pierron , Troy Brosnan , Ryan Pinkerton , and our team of mountain bike athletes, visit . Follow Monster Energy on YouTube , Facebook , Instagram , X , and TikTok for updates from the 2025 mountain bike season. For interview or photo requests, contact Kim Dresser . About Monster Energy Based in Corona, California, Monster Energy is the leading marketer of energy drinks and alternative beverages. Refusing to acknowledge the traditional, Monster Energy supports the scene and sport. Whether motocross, off-road, NASCAR, MMA, BMX, surf, snowboard, ski, skateboard, or the rock and roll lifestyle, Monster Energy is a brand that believes in authenticity and the core of what its sports, athletes, and musicians represent. More than a drink, it's the way of life lived by athletes, bands, believers, and fans. See more about Monster Energy including all of its drinks at . CONTACT: Kim Dresser C: (949) 300-5546 E: [email protected] SOURCE Monster Energy

Oct 12, 2025